Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women
Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females
Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.
This study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.
A total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.
Symptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.
The study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Abdelrahman F Senosy, MBBCh
- 电话号码:+02 010 95324741
- 邮箱:Abdelrahmanadam96@gmail.com
学习地点
-
-
Cairo Governorate
-
Cairo、Cairo Governorate、埃及、11511
- Ain Shams University Hospital
-
接触:
- Abdelrahman F Senosy, MBBCh
- 电话号码:+2 010 95324741
- 邮箱:Abdelrahmanadam96@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Female participants aged 18 to 70 years.
- Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.
- Failure of behavioral therapy and medical treatment for overactive bladder.
- Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Current use of medical treatment for overactive bladder.
- Cardiac pacemaker or metallic implant in the treatment area.
- Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.
- Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.
- Urinary bladder stones.
- Post-void residual urine volume greater than 100 mL.
- Lower urinary tract surgery within the previous 6 months.
- Previous pelvic radiation therapy.
- History of neuropathic disease.
- Pregnancy or planning to become pregnant.
- Hepatic, renal, or cardiac impairment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive active low-intensity extracorporeal shock wave therapy using the PiezoWave 2 focused extracorporeal shock wave therapy device.
Treatment will be administered once weekly for 6 weeks.
Before each session, participants will drink 1000 mL of water, and treatment will begin when the bladder reaches approximately 50% of the participant's functional bladder capacity, confirmed by bladder scan.
The probe will be placed over the lower abdomen approximately two fingerbreadths above the pubic symphysis and directed toward the bladder dome and bilateral bladder walls.
Each session will deliver 1000 impulses to each target area, for a total of 3000 impulses, at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
|
Focused low-intensity extracorporeal shock wave therapy will be delivered using the PiezoWave 2 device.
Each session will deliver a total of 3000 impulses at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
Treatment will be administered once weekly for 6 weeks.
|
|
假比较器:Sham Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive a sham procedure once weekly for 6 weeks.
The procedure will be similar to the active treatment in participant positioning, bladder preparation, probe placement, session duration, and device sound.
A sham probe or zero-energy device setting will be used so that no therapeutic shock wave energy is delivered.
|
A sham procedure will be administered using the same treatment setup, participant positioning, probe placement, session duration, and device sound as active therapy.
A sham probe or zero-energy setting will be used so that no therapeutic shock wave energy is delivered.
The procedure will be performed once weekly for 6 weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overactive Bladder Questionnaire 8-Item Total Score
大体时间:Baseline and 1 month after completion of the 6-week treatment
|
The Arabic-validated Overactive Bladder Questionnaire 8-Item (OAB-V8) will be completed at baseline and 1 month after completion of treatment.
The questionnaire contains 8 items scored from 0 to 5, giving a total score ranging from 0 to 40.
Higher scores indicate greater symptom-related bother.
The outcome will be calculated as the change in total OAB-V8 score from baseline to the 1-month assessment.
|
Baseline and 1 month after completion of the 6-week treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Post-Void Residual Urine Volume at 3 Months
大体时间:Baseline and 3 months after completion of treatment
|
Post-void residual urine volume will be measured by ultrasound after urination and recorded in milliliters.
The outcome will be calculated as the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Frequency Recorded in a 3-Day Voiding Diary
大体时间:Baseline and 3 months after completion of treatment
|
Participants will record the timing and number of urination episodes in a 3-day voiding diary.
The outcome will assess the change in urinary frequency from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Mean Voided Urine Volume Recorded in a 3-Day Voiding Diary
大体时间:Baseline and 3 months after completion of treatment
|
The volume of urine passed during each urination will be recorded in milliliters in a 3-day voiding diary.
Mean voided volume will be calculated, and the change from baseline to the 3-month follow-up assessment will be evaluated.
|
Baseline and 3 months after completion of treatment
|
|
Urgency Level Recorded in a 3-Day Voiding Diary
大体时间:Baseline and 3 months after completion of treatment
|
Participants will record the level of urinary urgency associated with each urination episode in a 3-day voiding diary.
The outcome will assess the change in recorded urgency level from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Leakage Episodes Recorded in a 3-Day Voiding Diary
大体时间:Baseline and 3 months after completion of treatment
|
The number of involuntary urinary leakage episodes will be recorded over 3 consecutive days.
The outcome will be calculated as the change in the number of leakage episodes from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Functional Bladder Capacity
大体时间:Baseline and 3 months after completion of treatment
|
Functional bladder capacity will be derived from measurements recorded in the participant's 3-day voiding diary and expressed in milliliters.
The outcome will assess the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- FMASU MS 434/2026
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.